Follow FrankTwisk on Twitter  






specifieke antilichamen

duiden mogelijk op

chronische "abortief-lytische"


bij een deel van

de CVS-patiŽnten







Epstein-Barr Virus


Epstein-Barr virus (EBV) is a human γ-herpesvirus

that is able to establish a long-term, latent infection in human B cells

for the life of the host.




Uit een zeer kleinschalige studie van Dr. Lerner, dr. Glaser en collega's blijkt dat

bij een deel van de patiŽnten met CVS sprake is van langdurige productie van

antilichamen tegen specifieke eiwitten die door het Epstein-Barr virus aangemaakt worden:

  • DNA polymerase:
  • een eiwit dat essentieel is om het DNA van het virus te vermenigvuldigen en

  • deoxyuridine triphosphate nucleotidohydrolase (dUTPase):
  • een eiwit dat genetische foutjes bij reproductie minimaliseert.

Volgens Lerner en collega's zijn deze antilichamen specifiek voor een

abortief-lytische EBV-infectie (gťťn volledige replicatie, wťl apoptose van gastheercellen).


Lerner heeft deze hypothese in onderstaand artikel beschreven (klik op afbeelding):




Het positieve van deze studie is het feit dat patiŽnten langer gevolgd werden.

Jammer genoeg werd slechts een kleine groep CVS-patiŽnten (6) onderzocht.





In een presentatie uit 2011 besteedde Lerner uitgebreid aandacht aan zijn theorie:



Klik op onderstaande afbeelding om de sheets te kunnen bekijken:




Klik op onderstaande afbeelding om deel 1 van de video te bekijken:




Klik op onderstaande afbeelding om deel 2 van de video te bekijken:





Citaten uit de studie:



The six CFS patients were identified as;

Group A EBV subset (five patients), and

Group B (one patient) who was co-infected with Borrelia burgdorferi [2].




The preliminary data demonstrate that

there is a prolonged elevated antibody level against a subset of patients with CFS,

suggesting that this antibody panel could be used to identify such patients.


We published the first evidence that the EBV-encoded dUTPase

is able to induce immune dysregulation in vitro

as demonstrated by its effect on the replication of PBMCS and

the production of several different proinflammatory cytokines

including IL-1β, TNF-α, IL-6, IL-8 and IL-10 [13].




In this study we demonstrate that

there is a statistically significant increase in antibody levels to

EBV EA-D complex, EBV-encoded dUTPase and EBV-encoded DNA polymerase

in repetitive longitudinal serum samples obtained from six CFS Group A EBV subset patients

studied over a consecutive period of 13Ė16 months

who were treated with valacyclovir when compared to a control group.




Both the Fluge [38] and Strayer studies [39] are consistent with the herpesvirus' CFS paradigm proposed by our group, and supported by the presence of elevated serum antibody to encoded proteins EBV DNA polymerase and EBV dUTPase reported here.




CFS patients have impaired NK cell function and numbers [17].


These NK changes may be either primary genetic, or

due to herpesvirus abortive lytic replication, we describe.




Patients with Group A CFS with subsets CMV or HHV6 do not respond to valacyclovir [2].


Likewise, Group B CFS patients with unrecognized co-infections do not respond to valacyclovir [2].







Antibody to Epstein-Barr virus deoxyuridine triphosphate nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue syndrome subset.

PLoS ONE. 2012;7(11): e47891. doi:10.1371/journal.pone.0047891.

Lerner AM, Ariza ME, Williams M, Jason L, Beqaj S, Fitzgerald JT, Lemeshow S, Glaser R.





Antibody to E

BV viral capsid antigen (VCA) IgM, EBV Diffuse Early Antigen EA(D), and

neutralizing antibodies against EBV-encoded DNA polymerase and EBV-encoded dUTPase

were assayed serially approximately every three months for 13Ė16 months

from sera obtained from patients with CFS (6) and

from sera obtained from twenty patients who had no history of CFS.





Antibodies to EBV EA(D) and

neutralizing antibodies against

the encoded-proteins EBV DNA polymerase and

deoxyuridine triphosphate nucleotidohydrolase (dUTPase)

were present in the EBV subset CFS patients.


Of the sera samples' obtained from patients with CFS

93.9% were positive for EA(D),

while 31.6% of the control patients were positive for EBV EA(D).


Serum samples were

positive for

neutralizing antibodies

against the EBV-encoded dUTPase (23/52; 44.2%) and

DNA polymerase (41/52; 78.8%)

in EBV subset CFS patients,

but negative in sera of controls.





There is

prolonged elevated antibody level

against the encoded proteins

EBV dUTPase and

EBV DNA polymerase

in a subset of CFS patients,

suggesting that

this antibody panel

could be used

to identify these patients,

if these preliminary findings

are corroborated by studies

with a larger number of

EBV subset CFS patients.;